<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154892">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02146391</url>
  </required_header>
  <id_info>
    <org_study_id>ZA-107</org_study_id>
    <nct_id>NCT02146391</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal</brief_title>
  <official_title>AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-WAY CROSSOVER STUDY TO EVALUATE THE EFFECT OF FOOD UPON THE PHARMACOKINETICS OF ANDROXAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, randomized, single-center, single-dose, two-way crossover study
      of the PK properties of Androxal in healthy male subjects. Twelve male subjects will each
      receive a single dose of Androxal 25 mg in both the fed and fasting state.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>â€¢ Cmax of a single dose of 25 mg of Androxal in male subjects in the fed state and fasted state.</measure>
    <time_frame>24 hour</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Normal Volunteers</condition>
  <arm_group>
    <arm_group_label>Androxal 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androxal 25 mg Capsules</intervention_name>
    <arm_group_label>Androxal 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Speak, read, and understand English or Spanish and is willing and able to provide
             written informed consent on an IRB-approved form prior to the initiation of any study
             procedures;

          2. Male; age 18-60 with a BMI of 25-42 kg/m2 inclusive

          3. No significant abnormal findings at the screening physical examination as evaluated
             by the Investigator;

          4. Normal laboratory values (or abnormal but not clinically significant) at screening as
             determined by the Investigator;

          5. Subject is willing to remain in the clinic for the screening visit and 2 overnight
             treatment visits (approximately 36 hours for the treatment visit)

          6. Must be able to swallow gelatin capsules;

          7. Must be willing to remain in the clinic for the treatment visits

        Exclusion Criteria:

          1. Known hypersensitivity to Clomid;

          2. Abnormal screening visit vital signs or clinical laboratory evaluation considered
             clinically significant by the Investigator;

          3. A hematocrit &gt;54% or a hemoglobin &gt;17 g/dL.

          4. Subject with a significant organ abnormality or disease as determined by the
             Investigator;

          5. Any medical condition that would interfere with the study as determined by the
             Investigator;

          6. Participation in a clinical trial with investigational medication within 30 days
             prior to study medication administration;

          7. An acute illness within 5 days of study medication administration;

          8. Positive urine drug screen at the screening visit;

          9. Known history of HIV and/or Hepatitis B or C

         10. Tobacco (nicotine products) use in the 3 months prior to the study;

         11. A mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study and/or evidence of an uncooperative attitude, as
             determined by the Investigator;

         12. History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary
             embolism);

         13. History of myocardial infarction, unstable angina, symptomatic heart failure,
             ventricular dysrhythmia, or known history of QTc interval prolongation;

         14. An employee or family member of an employee of the study site or the Sponsor;

         15. Previous participation in a clinical study of Androxal.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>May 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
